BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Huadong Medicine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Huadong Medicine's drugs run\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04879043-3296@assetmemo.bio
DTSTAMP:20261121T005950Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pamlectabart tismanitin: Phase 1/2 readout est. (NCT04879043)
DESCRIPTION:Pamlectabart tismanitin\, phase 1/2\, Multiple Myeloma.\nStudy:
  Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Mu
 ltiple Myeloma\nEstimated primary completion: March 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pamlectabart-tismanitin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04879043
URL:https://assetmemo.bio/drug/pamlectabart-tismanitin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07916480-1479@assetmemo.bio
DTSTAMP:20261121T005950Z
DTSTART;VALUE=DATE:20280427
DTEND;VALUE=DATE:20280428
SUMMARY:Roflumilast (Zoryve): Phase 3 readout est. (NCT07916480)
DESCRIPTION:Roflumilast (Zoryve)\, phase 3\, Atopic Dermatitis.\nStudy: Rof
 lumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis\nEstimated pr
 imary completion: 27 April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/roflumilast-zoryve#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07916480
URL:https://assetmemo.bio/drug/roflumilast-zoryve#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252440-784@assetmemo.bio
DTSTAMP:20261121T005950Z
DTSTART;VALUE=DATE:20281023
DTEND;VALUE=DATE:20281024
SUMMARY:Edaravone (TTYP01): Phase 2 readout est. (NCT07252440)
DESCRIPTION:Edaravone (TTYP01)\, phase 2\, Alzheimer's Disease.\nStudy: A S
 tudy to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Sympto
 matic Alzheimer's Disease\nEstimated primary completion: 23 October 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/edaravone-ttyp01#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07252440
URL:https://assetmemo.bio/drug/edaravone-ttyp01#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
